# Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

> **NCT05004831** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 54 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** fruquintinib plus TAS-102

## Key facts

- **NCT ID:** NCT05004831
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-11
- **Primary completion:** 2023-09
- **Final completion:** 2024-09
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004831, "Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05004831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*